Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.06 ^USD	-4.50%		+6.00%	+0.95%

Apr. 01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 26	Transcript : Quince Therapeutics, Inc. - Special Call

Cortexyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 10, 2022 at 04:50 pm EDT

Cortexyme, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 21.64 million compared to USD 23.09 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.78 a year ago.

Latest news about Quince Therapeutics, Inc.

Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Transcript : Quince Therapeutics, Inc. - Special Call	Mar. 26
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Quince Therapeutics, Inc. Launches Scientific Advisory Board	Feb. 22	CI
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	Feb. 15	CI
North American Morning Briefing : All Eyes on -2-	Nov. 21	DJ
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer	23-10-26	CI
Quince Therapeutics, Inc. Appoints Luca Benatti as Director	23-10-23	CI
Quince Therapeutics, Inc. acquired EryDel S.p.A	23-10-22	CI
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia	23-09-28	MT
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold	23-09-28	DJ
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex	23-09-28	CI
Quince Therapeutics Appoints Charles S. Ryan as President	23-09-06	CI
Insider Buy: Quince Therapeutics	23-08-11	MT
Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023	23-08-10	CI
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Sector Update: Health Care Stocks Declining Late Monday	23-07-24	MT
Sector Update: Health Care Stocks Easing Monday Afternoon	23-07-24	MT
Quince Therapeutics to Acquire EryDel in All-Stock Deal	23-07-24	MT
Quince Therapeutics, Inc. Announces Board and Executive Changes	23-07-24	CI
Quince Therapeutics, Inc. agreed to acquire EryDel S.p.A. for approximately $510 million.	23-07-23	CI
Quince Therapeutics Shares Rise Pre-Bell After Echo Lake Capital Raises Acquisition Offer	23-07-13	MT
Transcript : Quince Therapeutics, Inc. - Shareholder/Analyst Call	23-05-24
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI

Chart Quince Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patientâs own biology to deliver life-changing therapeutics to those living with rare diseases. The Companyâs asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patientâs own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The Company is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The Company also intends to investigate additional potential applications of the AIDE technology platform.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
QUINCE THERAPEUTICS, INC.	+0.95%	47.97M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research

Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Cortexyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

Latest news about Quince Therapeutics, Inc.

Chart Quince Therapeutics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research